Basel Medical Group Ltd shares surge 24.85% intraday after Roche's fenebrutinib shows promising results in Phase II trials.

Basel Medical Group Ltd. surged 24.85% intraday, with Roche's fenebrutinib showing promising results in Phase II studies for relapsing multiple sclerosis, maintaining no disability progression and low levels of disease activity for up to two years. Phase III studies for fenebrutinib in relapsing and primary progressive multiple sclerosis are expected to start reading out at year end.